Dr. Jeffrey Keith Lander, MD, PhD

Dr. Lander practices at Advanced Dermatology Of San Clemente INC in Dana Point, California.

Dr. Lander's NPI, 1174566046, was assigned on June 14, 2006. Dr. Lander graduated from University Of Minnesota Medical School in 2002. Dr. Lander holds California license A93332.

Dr. Lander's primary practice is Advanced Dermatology of San Clemente INC, at 34213 Pacific Coast Hwy, Dana Point, CA 92629-2875. The practice phone is (949) 248-4547.

Dr. Lander's primary practice is Advanced Dermatology Of San Clemente INC in Dana Point, California. The medical group on file is Orange Coast Dermatology. Dmand AI also links Dr. Lander to 7 more group practices and clinics and 7 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lander practices, 8 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Lander's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Lander is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Lander's licenses on file in 3 states: California, Minnesota and Washington.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses, itchy rashes and minor injury to a limb among the conditions Dr. Lander treats.

CMS data shows 3,910 Medicare services from Dr. Lander across 25 procedure codes in 2024, for 611 Medicare patients. Medicare paid $758,691 for them. Every service was in an office.

CMS counts 611 Medicare patients who saw Dr. Lander in 2024. The largest group is 75 to 84, with 273 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.10, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lander's median patient age at 72, with 48% women.

In 2024, Dr. Lander wrote 602 Medicare Part D claims for 372 patients. 99% of them were for generic drugs. CMS names the drug for 543 of them, across 5 drugs with 11 or more claims each, at $5,599 in total drug cost. In 2023, CMS named 451 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Lander for performance year 2024, reported as part of a group. Dr. Lander accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lander as offering telehealth. CMS counts 62 procedures of melanoma (skin cancer) excision by Dr. Lander, more than 89% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Lander. Dr. Lander's most frequent co-author is Mayha K. Patel.

CMS Open Payments shows 135 general payments to Dr. Lander from 33 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Novartis Pharmaceuticals Corporation paid the most, $411.

Dmand AI lists 3 awards for Dr. Lander, most recently CMS Stage 1 EHR in 2013.

Dr. Lander graduated from University Of Minnesota Medical School in 2002. Dr. Lander is a member of American Academy of Dermatology, American College of Mohs Surgery (ACMS) and ASDS.

Dr. Lander is in network with 10 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.